Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.

and PFS compared to concurrent CRT alone for newly diagnosed patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, does not affect other indications of the therapy. The FDA has accepted ...